Abstract: Serotonin signalling in the heart is mediated by receptor subtype 2B (5-HTR2B). A contribution of serotonin to valvular disease has been reported, but myocardial expression of 5-HTR2B and its role in canine dilated cardiomyopathy (DCM) is not known. The aim of the present study was to investigate myocardial 5-HTR2B mRNA expression in dogs with DCM and to correlate results with expression of markers for inflammation and remodelling. Myocardial samples from eight healthy dogs, four dogs with DCM, five with cardiac diseases other than DCM and six with systemic non-cardiac diseases were investigated for 5-HTR2B mRNA expression using quantitative PCR (qPCR). The results were compared to mRNA expression of selected cytokines, matrix metalloproteinases (MMP) and tissue inhibitors of matrix metalloproteinase (TIMP). Laser microdissection with subsequent qPCR and immunohistochemistry were employed to identify the cells expressing 5-HTR2B. The myocardium of control dogs showed constitutive 5-HTR2B mRNA expression. In dogs with DCM, 5-HTR2B mRNA values were significantly greater than in all other groups, with highest levels of expression in the left ventricle and right atrium. 
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. 2010; Lacerda et al., 2012a; Lacerda et al., 2012b) .
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The role of 5-HT and its receptors in canine DCM is not fully understood. Dilated 93 cardiomyopathy is associated with left ventricular dilatation and ventricular wall thinning, 94 therefore increasing wall stress. Increased ventricular wall stress is likely to stimulate 95 mechanoreceptors, which could cause local 5-HT production and increased 5-HTR2B 96 expression, as reported for valve leaflets exposed to tensile strain (Disatian and Orton, 2009; 97 Lacerda et al., 2012b ). This appears likely, since in rats, chronic 5-HT administration has 98 been shown to increase valvular 5-HTR2B transcription (Elangbam et al., 2008) . In humans 99 with heart failure, 5-HT plasma concentrations are also elevated, which has led to the 100 assumption that heart failure is mediated by 5-HTR2B (Jaffre et al., 2009; Shyu, 2009) . Fonfara et al., 2013a; Fonfara et al., 2013b) .
111
Considering these results and the characteristic pathological changes in canine DCM, we 112 hypothesize that the 5-HT system plays a role in the pathogenesis of canine DCM. We 113 therefore designed a study to investigate cardiac expression of 5-HTR2B and its association 114 with expression of IL-1, IL-6, TNF-α, TGF-β1, MMP-1, -2, -3, -13, TIMP-1 and -2,
115
comparing healthy control dogs with other groups of dogs affected with DCM, other cardiac 116 diseases or systemic non-cardiac disease.
118

Material and methods
119
Animals and tissues
120
Details of clinical cases are shown in Table 1 and consist of dogs affected with DCM
121
(group 2; n = 4), cardiac diseases other than DCM (group 3; n = 5) and dogs with systemic, 122 non-cardiac disease (group 4; n = 6) (Fonfara et al., 2013a; Fonfara et al., 2013b) . Eight 123 control Beagles (group 1a) were used for the quantitative PCR assay (four each entire male 124 and female, sourced from a pharmaceutical company with a median age of 2.75 years). The 
169
Samples were subsequently frozen at -20 °C for 18-22 h and subsequently RNA isolation was 170 performed using the RNeasy Minikit (Qiagen). (Table 2) .
234
The results of the RT-PCR performed on isolated cardiomyocytes of the LV of a dog 235 affected with DCM, showed that the cardiomyocytes were expressing 5-HTR2B mRNA and 236 the immunohistochemical staining of both control and diseased dogs confirmed that 237 cardiomyocytes also synthesised 5-HTR2B protein (Fig. 2) . Immunohistochemistry showed values concentrations were significantly greater than in all other groups (P = 0.002; Fig. 1 ).
251
This difference was primarily due to greater 5-HTR2B mRNA values concentrations in the 
Discussion
277
The present study assesses the constitutive expression of 5-HTR2B in the myocardium 278 of dogs and the changes in expression pattern and intensity in association with canine DCM.
279
The examination of control dogs showed that the myocardium constitutively expresses 5-
280
HTR2B, suggesting a role for 5-HT and its cardiac receptor in normal cardiac structure and 281 function (Nebigil et al., 2001; Nebigil et al., 2003; Liang et al., 2006) . There were no 282 significant differences in regional expression of 5-HTR2B mRNA, but a trend for higher 283 expression in the RA was observed.
285
Our results indicate that severe systemic diseases and non-DCM cardiac diseases do not
286
influence 5-HTR2B expression, whereas canine DCM is associated with a significant 287 increase in the RA and, to a lesser, but still significant extent, the LV. This 5-HTR2B 288 upregulation correlated with increased IL-1, IL-6, TNF-α, TGF-β1, MMP-2, MMP-13,
289
TIMP-1 and TIMP-2 mRNA expression. Using laser microdissection and immunohistology,
290
we were able to confirm that cardiomyocytes synthesize 5-HTR2B, which is similar to 291 previously reported results for canine MVD and cardiomyocytes in mice and humans (Choi 292 and Maroteaux, 1996; Kaumann and Levy, 2006; Liang et al., 2006; Disatian and Orton, 293 2009; Oyama and Levy, 2010; Orton et al., 2012) .
295
Serotonin, in association with increased 5-HTR2B and reduced SERT production, has HTR2B expression caused cardiac hypertrophy (Nebigil et al., 2001; Nebigil et al., 2003) .
301
Since the dogs with DCM in our study exhibited ventricular eccentric hypertrophy and were 302 all in decompensated CHF, these results may not be entirely contradictory, but are on the 303 other hand not fully comparable.
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In humans, CHF has been shown to be associated with an increase of 5-HT 
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